Suppr超能文献

2008 - 2017年美国商业保险成年人中阿片类药物使用障碍的治疗

Treatment Of Opioid Use Disorder Among Commercially Insured US Adults, 2008-17.

作者信息

Shen Karen, Barrette Eric, Dafny Leemore S

机构信息

Karen Shen is a PhD student in economics at Harvard University, in Cambridge, Massachusetts.

Eric Barrette is a director, health economics, at Medtronic in Washington, D.C.

出版信息

Health Aff (Millwood). 2020 Jun;39(6):993-1001. doi: 10.1377/hlthaff.2019.01041.

Abstract

There is abundant literature on efforts to reduce opioid prescriptions and misuse, but comparatively little on the treatment provided to people with opioid use disorder (OUD). Using claims data representing 12-15 million nonelderly adults covered through commercial group insurance during the period 2008-17, we explored rates of OUD diagnoses, treatment patterns, and spending. We found three key patterns: The rate of diagnosed OUD nearly doubled during 2008-17, and the distribution has shifted toward older age groups; the likelihood that diagnosed patients will receive any treatment has declined, particularly among those ages forty-five and older, because of a reduction in the use of medication-assisted treatment (MAT) and despite clinical evidence demonstrating its efficacy; and treatment spending is lower for patients who choose MAT. These patterns suggest that policies supporting the use of MAT are critical to addressing the undertreatment of OUD among the commercially insured and that further research to assess the cost-effectiveness of treatment with versus without medication is needed.

摘要

关于减少阿片类药物处方及滥用的努力,已有大量文献,但针对阿片类药物使用障碍(OUD)患者的治疗方面的文献相对较少。利用2008年至2017年期间代表1200万至1500万通过商业团体保险覆盖的非老年成年人的理赔数据,我们探究了OUD诊断率、治疗模式及支出情况。我们发现了三个关键模式:2008年至2017年期间,确诊的OUD发病率几乎翻了一番,且分布已转向年龄较大的群体;由于药物辅助治疗(MAT)的使用减少,尽管有临床证据证明其疗效,但确诊患者接受任何治疗的可能性下降,尤其是在45岁及以上的人群中;选择MAT治疗的患者的治疗费用较低。这些模式表明,支持使用MAT的政策对于解决商业保险人群中OUD治疗不足的问题至关重要,并且需要进一步研究以评估使用药物与不使用药物治疗的成本效益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验